Leading Indian pharma firms are rationalizing operations and work forces to rein in costs and improve efficiency and profitability in a tough overall operating environment. Sun Pharma, which has declared an 'unwavering focus' on cost control, recently ended operations at two Indian clinical pharmacology units.
A proposal to increase the minimum public shareholding in listed firms in India, if implemented, is expected to impact the subsidiaries of GlaxoSmithKline, Novartis and AstraZeneca in the country, as well as local firms like Cadila Healthcare. Some of the foreign firms may well consider delisting
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.